Search PubMed⌕ Search

Biomedical subjects

G Katona

Publications and source records attributed to G Katona.

At least 37 records · Page 2Linked to original sources
PubMed1987

A clinical trial of glycosaminoglycan-peptide complex ('Rumalon') in patients with osteoarthritis of the knee.

A clinical trial was undertaken in 50 patients with osteoarthritis of the knee to assess the therapeutic value of glycosaminoglycan-peptide complex in treatment. The first year consisted of a randomized, double-blind, placebo-controlled, parallel-group trial (25 patients in each group), after which all patients received active treatment for a further 2 years. Treatment consisted of three 8-week courses in the first year and 2 such courses per year in subsequent years, each consisting of 2 ml intramuscular injections given 3 times per week. Patients were permitted to continue taking anti-inflammatory drugs and to receive physiotherapy during the trial period. At the end of the first year of the trial (double-blind phase), there were no significant differences between the two treatment groups. However, after the second year, those patients who had received glycosaminoglycan-peptide complex for 2 years had significantly greater improvements in night pain and rest pain than did those who had received active treatment for only 1 year. At the end of 3 years (when half the patients had received active treatment for 2 years and half for 3 years), there were significant overall improvements in relation to rest pain, pain on walking and morning stiffness, but not in respect to night pain, pain on standing or climbing stairs. At the same time, improvements were seen in radiological severity of disease (assessed double-blind) in 16% of patients, with 'no change' in 74% and deterioration in 10%, these figures being considerably better than might be expected with conventional therapy. Glycosaminoglycan-peptide complex was extremely well tolerated.

Aged↗
PubMed1985

Anterior spinal flexion in healthy Mexican children.

We investigated anterior spinal flexion (ASF) in a group of 250 healthy Mexican children (125 boys and 125 girls) aged from 6 to 15 years using the Schober's and Macrae and Wright's techniques and 4 new variants. Two of these variants were the more reliable methods of measuring the ASF in children. Marks either 5 cm (Method 3) or 10 cm (Method 4) above and 2.5 cm below the lumbosacral junction were made in the midline of the back with the children standing upright. After bending their trunks, the distraction between the inferior and superior marks was measured. ASF did not increase nor decrease with age. Highest values were found in boys. Values of at least 4 and 6 cm for boys and 3 and 5 cm for girls using Methods 3 and 4 are required to consider ASF in children aged from 6 to 15 as normal.

Adolescent↗
PubMed1985

The choice of the ideal anti-inflammatory drug.

The selection of the ideal anti-inflammatory drug is an important task bearing in mind some of the characteristics concerning its pharmacokinetics, mechanism of action, efficacy, tolerability, dosage, safety, presentation and route of administration, patient compliance and patient expectancy. The present paper deals with each of these topics, based on current knowledge of the different anti-inflammatory drugs and the more than 20 years experience in a great number of clinical trials with most of the best known non-hormonal anti-inflammatory compounds.

Anti-Inflammatory Agents↗
PubMed1984

Osteoarthritis--an inflammatory disease?

From a study of 160 cases of osteoarthritis (OA), including photographs from gross examination, arthroscopy, radionuclide scanning and histological preparations including crystal deposits from synovial fluid, it is concluded that OA may be regarded as an inflammatory condition for which the use of non-steroidal antiinflammatory drugs rather than pure analgesics should be encouraged.

Arthroscopy↗
PubMed1983

Sequential quantitative joint scintigraphy in the investigation of anti-inflammatory effects of piroxicam.

Ten patients with rheumatoid arthritis were given piroxicam in a single daily dose of 20-40 mg for 16 weeks. The average number of painful joints decreased from 16.7 to 4.0. Similar reductions were seen in the number of inflamed joints and number of tender joints. Scintigraphic study of the patients revealed a clear reduction in 99TC uptake suggesting significant anti-inflammatory activity of the drug.

Anti-Inflammatory Agents↗
PubMed1983

Double-blind crossover study to evaluate the efficacy of a single daily dose of naproxen in rheumatoid arthritis.

Three dosage schedules of naproxen--1000 mg in the morning and placebo in the evening, 1000 mg in the evening and placebo in the morning, and 500 mg in the morning and again in the evening--were compared for efficacy in treating rheumatoid arthritis in a 13-week, double-blind, crossover study. After a 1-week washout, 48 patients were assigned randomly according to a Latin Square design to one of three dosage sequence groups, each consisting of three 4-week treatment phases. Each group experienced decreases in pain, number of affected joints, morning stiffness, ARA classification, and disease activity evaluated by both patient and physician. The three dosage schedules provided the same therapeutic results, with few and mild side effects. This study indicates that a single daily dose of naproxen can be used to treat rheumatoid arthritis safely and effectively.

Adult↗
PubMed1983

L-deprenyl in the treatment of Parkinson's disease.

The experiences of a six years' follow-up study with L-Deprenyl are summarized. L-Deprenyl may be effective in influencing the very early Parkinsonian symptoms but usually levodopa derivates must be given in addition. In the course of substitution therapy L-Deprenyl successfully replaces about 30% of levodopa administered to optimally treated patients. Concerning the "on-off" phenomena L-Deprenyl seems to be beneficial in the mild forms of "end-of-dose deterioration".

Aged↗
PubMed1981

Double-blind comparative trial of indoprofen and acetylsalicylic acid in osteoarthritis.

The effectiveness, safety and acceptability of indoprofen (IP) and acetylsalicylic acid (ASA) were assessed in patients with osteoarthritis, in a double-blind comparative trial. Each patient received IP 600 mg/day or ASA 2100 mg/day for a four-week period; after a one-week wash-out period, the same drug was given at a higher dosage (IP 800 or ASA 2800 mg/day) for another four weeks. Seventeen patients on indoprofen and 14 on SAS completed the trial. A significant improvement was obtained with indoprofen in the different parameters measuring pain, from the first treatment period; results were similar at the end of the second period. Results with ASA, at both dosages, appeared less impressive. Two patients on indoprofen and five on ASA complained of side effects.

Adult↗
PubMed1979

Hereditary tyrosinemia.

Explore the source record for details and available documents.

Amino Acid Metabolism, Inborn Errors↗